Acadia misses mark in Alzheimer's but continues phase 3 program
Acadia Pharmaceuticals' drug missed the mark in a mid-stage Alzheimer's psychosis study, but the company said it saw enough signal to continue with a modified Phase 3 program.
Acadia Pharmaceuticals
Develops and commercializes medicines for neurological disorders and rare diseases, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and Rett syndrome.
Company Info
Sector:Small Molecule Pharma
Headquarters:San Diego, California, USA
Founded:1993
Website:acadia.com/en-us
Clinical Development Pipeline
NUPLAZID (pimavanserin)
Target: 5-HT2A inverse agonistDAYBUE (trofinetide)
Target: IGF-1 pathwayACP-204
Target: 5-HT2A inverse agonistRecent News
Leadership Team
Catherine Owen Adams
Chief Executive Officer
Serge Stankovic
President